319 related articles for article (PubMed ID: 36597704)
1. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
[TBL] [Abstract][Full Text] [Related]
2. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
3. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
[TBL] [Abstract][Full Text] [Related]
4. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
Zhu ZG
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
9. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
Front Immunol; 2022; 13():992060. PubMed ID: 36311733
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic advances in gastric cancer.
Yoneda A; Kuroki T; Eguchi S
Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
[TBL] [Abstract][Full Text] [Related]
11. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.
Yao G; Yuan J; Duan Q; Tan Y; Zhang Q; Chen D; Chen J
Invest New Drugs; 2024 Feb; 42(1):1-13. PubMed ID: 37971628
[TBL] [Abstract][Full Text] [Related]
12. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
13. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
14. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
15. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
[TBL] [Abstract][Full Text] [Related]
16. Adenosine signaling: Optimal target for gastric cancer immunotherapy.
Wang J; Du L; Chen X
Front Immunol; 2022; 13():1027838. PubMed ID: 36189223
[TBL] [Abstract][Full Text] [Related]
17. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
18. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
[TBL] [Abstract][Full Text] [Related]
19. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
Zouein J; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]